Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 10,946B 69.35B 62.11B 57.3B 51.86B 96.97B 6,604B 98.53B 684B 273B 3,456B 260B 255B P/E 2026 *
21.5x
P/E 2027 * 19x
Enterprise Value 9,948B 63.02B 56.45B 52.08B 47.13B 88.13B 6,002B 89.55B 621B 248B 3,141B 237B 231B EV / Sales 2026 *
7.14x
EV / Sales 2027 * 6.45x
Free-Float
38.12%
Yield 2026 *
2.03%
Yield 2027 * 2.29%
1 day+0.59%
1 week+2.18%
Current month+6.88%
1 month+4.57%
3 months-4.94%
6 months-16.21%
Current year-19.29%
1 week 6,522
Extreme 6522
6,897
1 month 5,974
Extreme 5974
6,897
Current year 5,974
Extreme 5974
10,700
1 year 5,974
Extreme 5974
10,700
3 years 4,259
Extreme 4259
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.333333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%+2.18%-3.48%+48.90% 68.78B
+6.63%+8.10%+67.50%+145.20% 1,148B
+1.53%+6.76%+47.22%+89.01% 652B
+1.68%+2.10%+27.80%+109.31% 505B
+0.73%+2.47%+53.85%+68.96% 384B
+3.83%-2.37%+68.14%+42.32% 348B
+2.38%+4.27%+33.81%+57.95% 294B
+2.26%+3.47%+5.21%+28.92% 264B
+1.97%+5.11%+57.74%+76.14% 244B
+4.03%+7.84%+40.49%+116.14% 197B
Average +2.81%+1.41%+39.83%+78.29% 410.59B
Weighted average by Cap. +3.60%+1.51%+48.69%+95.18%

Financials

2026 *2027 *
Net sales 1,393B 8.82B 7.9B 7.29B 6.6B 12.34B 840B 12.54B 86.99B 34.7B 440B 33.11B 32.41B 1,522B 9.64B 8.64B 7.97B 7.21B 13.48B 918B 13.7B 95.06B 37.92B 481B 36.19B 35.42B
Net income 510B 3.23B 2.89B 2.67B 2.41B 4.51B 307B 4.59B 31.83B 12.7B 161B 12.12B 11.86B 577B 3.65B 3.27B 3.02B 2.73B 5.11B 348B 5.19B 36.03B 14.37B 182B 13.71B 13.42B
Net Debt -998B -6.32B -5.66B -5.22B -4.73B -8.84B -602B -8.98B -62.33B -24.87B -315B -23.73B -23.22B -1,130B -7.16B -6.41B -5.91B -5.35B -10.01B -681B -10.17B -70.55B -28.15B -357B -26.86B -26.28B
Projected Income Statement - Annual - Chugai Pharmaceutical Co., Ltd.
Logo Chugai Pharmaceutical Co., Ltd.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Employees
5,104
Date Price Change Volume
29/10/26 JP¥6,653.00 +0.59% 4,547,300
28/10/26 JP¥6,614.00 -1.11% 3,542,700
27/10/26 JP¥6,688.00 -3.03% 3,220,000
26/10/26 JP¥6,897.00 +1.50% 3,324,200
23/10/26 JP¥6,795.00 +2.74% 5,542,700
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Chugai Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,653.00JPY
Average target price
8,446.67JPY
Spread / Average Target
+26.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Chugai Pharmaceutical Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4519 Stock